CAS NO: | 1562024-11-6 |
包装 | 价格(元) |
10mM (in 1mL DMSO) | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
Cas No. | 1562024-11-6 |
Canonical SMILES | O=C(N)C1=CC=C(N2N=C(C)C3=C2CC(C)(C)CC3=O)C=C1NCCCOCCOCCOCCOCCOCCCNC(NC4=CC5=C(C6(C7=C(OC8=C6C=CC(O)=C8)C=C(O)C=C7)OC5=O)C=C4)=S |
分子式 | C52H60N6O12S |
分子量 | 993.13 |
溶解度 | DMSO: 125 mg/mL (125.86 mM) |
储存条件 | Store at -20℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | HS-27, a fluorescently-tethered Hsp90 inhibitor, assays surface Hsp90 expression on intact tissue specimens. HS-27 is made up of the core elements of SNX-5422, an Hsp90 inhibitor, tethered via a PEG linker to a fluorescein derivative (fluorescein isothiocyanate or FITC), that binds to ectopically expressed Hsp90. HS-27 has potential use in a see-and-treat paradigm in breast cancer[1]. HS-27 labels all receptor subtypes of breast cancer, but not normal cells, and specifically binds to Hsp90 expressed on the surface of breast cancer cells before being internalized. HS-27 fluorescence is greater in tumor than non-tumor tissue[1]. [1]. Crouch BT, et al. Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer. Sci Rep. 2019 Mar 5;9(1):3461. |